Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study  by Wijesooriya, N Saman et al.
Articles
www.thelancet.com/lancetgh   Vol 4   August 2016 e525
Global burden of maternal and congenital syphilis in 2008 
and 2012: a health systems modelling study
N Saman Wijesooriya, Roger W Rochat, Mary L Kamb, Prasad Turlapati, Marleen Temmerman, Nathalie Broutet, Lori M Newman
Summary
Background In 2007, WHO launched a global initiative for the elimination of mother-to-child transmission of syphilis 
(congenital syphilis). An important aspect of the initiative is strengthening surveillance to monitor progress towards 
elimination. In 2008, using a health systems model with country data inputs, WHO estimated that 1·4 million 
maternal syphilis infections caused 520 000 adverse pregnancy outcomes. To assess progress, we updated the 2008 
estimates and estimated the 2012 global prevalence and cases of maternal and congenital syphilis.
Methods We used a health systems model approved by the Child Health Epidemiology Reference Group. WHO and 
UN databases provided inputs on livebirths, antenatal care coverage, and syphilis testing, seropositivity, and treatment 
in antenatal care. For 2012 estimates, we used data collected between 2009 and 2012. We updated the 2008 estimates 
using data collected between 2000 and 2008, compared these with 2012 estimates using data collected between 2009 
and 2012, and performed subanalyses to validate results.
Findings In 2012, an estimated 930 000 maternal syphilis infections caused 350 000 adverse pregnancy outcomes 
including 143 000 early fetal deaths and stillbirths, 62 000 neonatal deaths, 44 000 preterm or low weight births, and 
102 000 infected infants worldwide. Nearly 80% of adverse outcomes (274 000) occurred in women who received 
antenatal care at least once. Comparing the updated 2008 estimates with the 2012 estimates, maternal syphilis 
decreased by 38% (from 1 488 394 cases in 2008 to 927 936 cases in 2012) and congenital syphilis decreased by 39% 
(from 576 784 to 350 915). India represented 65% of the decrease. Analysis excluding India still showed an 18% 
decrease in maternal and congenital cases of syphilis worldwide.
Interpretation Maternal and congenital syphilis decreased worldwide from 2008 to 2012, which suggests progress 
towards the elimination of mother-to-child transmission of syphilis. Nonetheless, maternal syphilis caused substantial 
adverse pregnancy outcomes, even in women receiving antenatal care. Improved access to quality antenatal care, 
including syphilis testing and treatment, and robust data are all important for achieving the elimination of mother-to-
child transmission of syphilis.
Funding The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and 
Research Training in Human Reproduction in WHO, and the US Centers for Disease Control and Prevention.
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license.
Introduction
Syphilis, a bacterial infection caused by the spirochete 
Treponema pallidum, can be transmitted sexually or from 
mother to child in utero. Untreated primary or secondary 
syphilis infections can induce catastrophic fetal outcomes 
in the second or third trimesters of pregnancy.1 Most 
maternal syphilis infections are latent (asymptomatic), 
but still result in poor pregnancy outcomes in more than 
50% of cases.2–5 Syphilis-associated adverse pregnancy 
outcomes (ie, congenital syphilis) include early fetal 
death, stillbirth, preterm birth, low birthweight, neonatal 
death, and congenital infection in infants.
A combination of serological tests measuring infection 
activity and conﬁ rming exposure to T pallidum can detect 
asymptomatic syphilis infections in pregnant women. 
Maternal syphilis screening and treatment of seropositive 
women with at least 2·4 million units of benzathine 
penicillin prevents most adverse pregnancy outcomes if 
provided suﬃ  ciently early (ie, >30 days before delivery).6 
As a public health intervention, antenatal syphilis 
screening and treatment is cost-saving in moderate and 
high prevalence settings, and cost-eﬀ ective even when 
prevalence is less than 1%.7–10
Unfortunately, congenital syphilis is much harder to 
diagnose than syphilis in pregnant women, and therefore 
estimates are needed to accurately reﬂ ect burden of 
disease in most countries. Global maternal and congenital 
syphilis estimates were published in 2007 using peer-
reviewed and unpublished country reports available from 
31 countries from 1997 to 2003 in which studies used 
serologically conﬁ rmed tests in antenatal care attendees. 
The 2007 estimates suggested that more than 2 million 
maternal and 1·5 million congenital syphilis cases would 
occur every year worldwide without treatment.11 These 
estimates served as the basis for the 2007 launch of a 
global initiative for the elimination of mother-to-child 
transmission of syphilis and congenital syphilis, which 
has resulted in worldwide policy and programme changes.
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In 2008, the WHO and global partners introduced 
surveillance of syphilis in pregnancy within the HIV 
Universal Access and Global AIDS Response Progress 
Reporting (UA/GARPR) system to monitor progress. 
Countries were encouraged to report data for three core 
indicators collected on antenatal care attendees: syphilis 
testing, seropositivity, and treatment (added in 2010).12
To measure progress for the new initiative, the 2008 
baseline global and regional estimates of syphilis in 
pregnancy used antenatal syphilis seropositivity data 
reported by 96 countries to the UA/GARPR. These 
2008 estimates noted 1·4 million maternal and 
520 000 congenital syphilis infections, including 
304 000 perinatal deaths, occurred globally.13 The 2008 
estimates uniformly adjusted for seropositivity to 
minimise overdiagnosis of active syphilis. Furthermore, 
the 2008 estimates used ﬁ xed regional assumptions for 
testing and treatment coverage.
We aimed to estimate the global and regional cases 
and prevalence of maternal and congenital syphilis in 
2012. With stronger surveillance and better country-
level reporting over time, we also used the same method 
to revise the 2008 (baseline) estimates, and compared 
these updated 2008 estimates with the new 2012 
estimates to assess progress made in the global 
elimination initiative.
Methods
Data inputs
In this analysis we used a health systems model 
approved by the Child Health Epidemiology Reference 
Group in June, 2011, and by technical experts at the 
WHO meeting on sexually transmitted infection 
estimates held in November, 2013. Whenever possible, 
we used actual country data reported by the 194 WHO 
member states and where data were not available, we 
imputed numbers based on regional estimates 
(appendix); where no data were available for southern 
Latin America, we used the regional mean for tropical 
Latin America; where no data were available for high-
income North America, Australasia, or high-income 
Asia Paciﬁ c, we used the regional mean for western 
Europe; where no data were available for east Asia, we 
used the regional mean for southeast Asia. For each 
country, we obtained the numbers of livebirths 
from the United Nations Development Programme 
World Population Prospects database.14 Cousens and 
colleagues15 provided the estimated national numbers 
of stillbirths (deﬁ ned as fetal death in the third 
trimester, with fetal weight at least 1000 g or gestation 
at least 28 completed weeks).
We obtained antenatal clinic attendance (at least one 
visit) from the WHO Global Health Observatory.16 
Research in context
Evidence before this study
In 2007, WHO launched the global Elimination of Congenital 
Syphilis initiative, with a goal of reducing mother-to-child 
transmission of syphilis to a suﬃ  ciently low level that congenital 
syphilis was no longer a public health problem. The goal is for 
countries to achieve a congenital syphilis rate of 50 or fewer cases 
per 100 000 livebirths through achieving programmatic targets 
of more than 95% syphilis screening coverage in pregnancy and 
more than 95% treatment of seropositive women. In 2008, 
surveillance of syphilis in pregnancy was included within the HIV 
Universal Access and Global AIDS Response Progress Reporting 
(UA/GARPR) system. Countries were encouraged to report data 
for three core indicators collected on antenatal care attendees: 
syphilis testing, seropositivity, and treatment. Baseline global and 
regional estimates of syphilis in pregnancy for 2008, which used 
antenatal syphilis seropositivity data reported by 96 countries to 
the UA/GARPR, found 1·4 million maternal and 
520 000 congenital syphilis infections globally, including 
304 000 perinatal deaths. In this analysis, we used the most 
recently collected GARPR data (2009–12) for key congenital 
syphilis indicators for 2012 estimates, and compared these 
against 2008 updated baseline data from GARPR (2000–08), 
the start of the elimination eﬀ ort.
Added value of this study
The ﬁ ndings of our current analysis add value to the existing 
body of evidence by providing a 5-year, interim report on 
progress made with the launch of the global initiative for the 
elimination of congenital syphilis. The analysis found a 
38% reduction in the number of pregnant women with 
syphilis and in the number of congenital syphilis cases. 
Global monitoring improved from 2008 to 2012, with more 
countries reporting on sexually transmitted infection 
indicators. Nonetheless, certain countries experienced 
challenges and may need support. Updated estimates of the 
baseline global burden of maternal and congenital syphilis 
(2008) using GARPR data were available for more countries. 
The study presents an acceptable model vetted by experts for 
estimating progress on the global elimination of congenital 
syphilis initiative for use in future updates.
Implications of all the available evidence
These results help policy makers and leaders understand 
where challenges remain and can be addressed. They can be 
used for broader global maternal and child health 
programmes, in which the extent of congenital syphilis (still 
accounting for almost 200 000 perinatal deaths each year) is 
often overlooked. Regions and countries can use our data to 
advocate for the needed resources to carry out routine 
screening of syphilis in antenatal care in all countries, 
including some newer screening applications such as dual 
rapid HIV and syphilis tests on a single device, and to estimate 
treatment needs. 
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We used most recently collected UA/GARPR data from 
2000–08 for updated 2008 and 2009–12 for 2012 
estimates. The UA/GARPR provided country data for 
three variables: syphilis seropositivity with speciﬁ ed test 
type (non-treponemal, treponemal, or both), testing of 
antenatal care attendees for syphilis, and treatment of 
syphilis seropositive antenatal care attendees. When 
seropositivity data were unavailable, we searched 
PubMed for peer-reviewed reports and the grey literature 
between Jan 1, 2000, and March 18, 2014, using the search 
terms (“syphilis” OR “treponemal” OR “non-treponemal” 
AND “[country name]” and added [“pregnant” OR 
“perinatal” OR “antenatal”]. This search provided 
seropositivity data for eight countries.17–24 For updated 
2008 estimates, we used the testing data with the 
treatment assumption used for the original 2008 
estimates.13 When data were unavailable for these 
variables, we used the most recent country values to 
calculate regional means for 21 Institute for Health 
Metrics and Evaluation (IHME) regions for imputation. 
IHME regions categorise countries based on 
epidemiological similarity and geographical proximity.25 
However, we presented these data for the six WHO 
regional groupings to facilitate WHO regional 
programmatic and planning processes.
The appendix shows the model input values and 
regional means by WHO and IHME regions used to 
generate the updated 2008 and 2012 estimates. We used 
the following assumptions based on published scientiﬁ c 
literature to generate estimates: ﬁ rst, we deﬁ ned probable 
active syphilis infections as cases reactive on both 
treponemal and non-treponemal serological tests. We 
applied separate correction factors for four diﬀ erent 
scenarios by the country-speciﬁ ed test type to adjust for 
possible error due to the diagnostic test type used: both 
reactive non-treponemal and reactive tests (1·0); 
only reactive non-treponemal (0·522); only reactive 
treponemal tests (0·536); and neither test reported 
(0·686; appendix). This correction factor was based on a 
random eﬀ ects modelling analysis of positivity data 
obtained through a recent review of the scientiﬁ c 
literature.26
Second, the number of early fetal deaths (deﬁ ned as 
occurring at 22 through 28 weeks’ gestation) was 
estimated at 20% of stillbirths based on the relationship 
of early to late fetal deaths recorded in multicountry 
reviews (mainly high-income countries).15,27,28 We 
estimated the number of pregnancies by summing 
livebirths, stillbirths, and early fetal deaths.
Third, the expected proportions of pregnancies 
resulting in any adverse pregnancy outcomes (52%) 
included early fetal deaths or stillbirths (21%), preterm 
(born alive before 37 weeks’ gestation) or low birthweights 
(weighing <2500 g; 6%), neonatal death (death in ﬁ rst 
28 days; 9%, or clinical disease in infants (29–365 days; 
16%, of syphilis-infected women and were based on a 
recent meta-analysis.3
Finally, the eﬀ ectiveness of penicillin at preventing any 
adverse pregnancy outcome (84%, the weighted average 
using the expected proportions as the weights) included 
early fetal deaths or stillbirths (82%), preterm or low 
birthweights (64%;, neonatal deaths (80%, and clinical 
disease in infants (97%, and was based on a published 
literature review.6
In sum, this method for updated 2008 and 
2012 estimates was identical to the health systems model 
used for the original WHO 2008 estimates except that it 
used newly available, country-reported testing data and 
country-reported treatment data (2012 only); a more 
nuanced, evidence-based correction factor for test type; 
and IHME regional classiﬁ cations for imputing means 
rather than medians for countries without data.13
Analyses
We used a four-step process to estimate for 2012, and 
update for 2008, the number of pregnant women with 
probable active syphilis infections and associated adverse 
pregnancy outcomes for each country. We summed 
country values to N, where N equals the number of 
countries for each of the six WHO regions and 194 WHO 
member countries for the global total.
For step 1 we estimated the number of pregnant 
women with probable active syphilis infections.
In step 2 we estimated the number of pregnant women 
with probable active syphilis infections attending 
antenatal care;
among antenatal care attendees, we estimated the 
numbers of pregnant women with syphilis infections 
who were not tested; tested but not treated; and tested 
and treated for syphilis:
ΣPASIc, where PASIc =(Posc) (cfc) (pregc)
c=1
N
Σ
c=1
N
PASI_ANCc, where PASI_ANCc =(PASIc)(ANC1c)
PASI_ANC_NTc, where PASI_ANC_NTc =
(PASI_ANCc) (1–Testedc)
Σ
c=1
N
Σ
c=1
N
(PASI_ANCc)(Testedc)(Treatedc) PASI_ANC_TTc,Σ
c=1
N
=(PASI_ANCc)(Testedc)(Treatedc)
(PASI_ANCc)(Testedc)(1–Treatedc)
PASI_ANC_TTc, wherePASI_ANCTTc =
where PASI_ANC_TTc
PASI_ANC_TNTc, wherePASI_ANC_TNTc  =Σ
c=1
N
PASI_ANC_TNTc, where PASI_ANC_TNTc  =Σ
c=1
N
(PASI_ANCc)(Testedc)(1–Treatedc)
See Online for appendix
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And for pregnant women with syphilis who did not 
access antenatal care services.
In step 3, we estimated the numbers of adverse 
pregnancy outcomes for syphilis-infected pregnant 
women attending antenatal care who were not tested; 
tested but not treated; and tested and treated but in 
whom treatment was ineﬀ ective at preventing an adverse 
pregnancy outcome:
And for pregnant women with syphilis who did not 
access antenatal care services:
For step 4, for the total number of adverse outcomes 
associated with syphilis in pregnancy, we summed 
adverse outcomes among women who did not attend 
antenatal care and antenatal care attendees who were not 
tested, tested but not treated, and tested and treated for 
syphilis:
To calculate maternal and congenital syphilis 
prevalence, we divided the respective case estimates by 
the estimated number of pregnancies.
For analytical purposes, we calculated the percent 
change between updated 2008 and 2012 estimates 
worldwide, for six WHO regions, and 194 countries to 
examine which countries were driving the global change.
To assess robustness of trends in the number of 
pregnant women with active syphilis infections from the 
updated 2008 to 2012 estimates, we did two additional 
analyses: all countries, irrespective of whether data were 
reported values or regional means (to compare the overall 
diﬀ erences between estimates); and only countries with 
seropositivity values in both updated 2008 and 
2012 estimates (to assess trends in consistently reporting 
countries).
We did the same two analyses for adverse pregnancy 
outcomes for countries reporting seropositivity and 
testing data in both time periods and also included 
countries with reported treatment data in 2012. To assess 
the validity of the treatment assumption used in updated 
2008 estimates, we recalculated proportions using the 
2012 treatment data. To describe the burden of syphilis 
based on the global distribution of wealth, we stratiﬁ ed 
countries by World Bank income groups.29
We did not perform a formal uncertainty analysis as 
there were insuﬃ  cient data beyond those used in this 
analysis to allow for evidence-based calculation of 
uncertainty.
Role of the funding source
The funders had no role in the study design, conduct, 
analysis, or writing of the manuscript. The corresponding 
author had full access to the data and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
From 2008 to 2012, the number of reporting countries 
increased from 88 to 122 for syphilis seropositivity, nine 
to 47 for test type, 58 to 106 for testing, and zero (not 
reported until 2010) to 74 countries for treatment. Data 
availability increased in all WHO regions. In 2012, 
ΣPASI_NOANCc, where PASI_NOANC =
c=1
N
(PASIc) (1–ANC1c)
ΣAO_ANC_NTc, where AO_ANC_NTc =
c=1
N
(PASI_ANC_NTc) (PEFD,SB + PP,LBW + PNND + PI)
ΣAO_ANC_TNTc, where AO_ANC_TNTc =
c=1
N
(PASI_ANC_TNTc) (PEFD,SB + PP,LBW + PNND + PI)
ΣAO_ANC_TTc, where AO_ANC_TTc =
c=1
N
(PASI_ANC_TTc) ((PEFD,SB) (((PEFD,SB) (1 – EEFD,SB))+
((PP,LBW) (1 – EP,LBW))+ (1 – ENND))+ ((PI) (1 – EI)) )
ΣAO_NOANCc, where AO_NOANCc =
c=1
N
(PASI_NOANCc) (PEFD,SB + PP,LBW + PNND+ PI)
ΣAO, where AOc =AO_NOANCc + AO_ANC_NTc +
c=1
N
AO_ANC_TNTc + AO_ANC_TTc
Figure 1: Estimated numbers of syphilis-associated adverse pregnancy outcomes by WHO region in 2008 
and 2012
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 Figure 2: Estimated number of maternal syphilis cases and prevalence by WHO region
Figure 3: Estimated number of syphilis-associated adverse pregnancy outcome by WHO region
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we estimated that 927 936 pregnant women 
(0·66% prevalence) had probable active syphilis 
infections, resulting in 350 915 adverse pregnancy 
outcomes. These outcomes included 143 100 early fetal 
deaths, 44 132 preterm or low birthweight infants, 
61 870 neonatal deaths, and 101 813 infected infants 
(ﬁ gure 1; for the full country dataset see appendix).
The distribution of maternal syphilis infections and 
adverse outcomes varied across regions (ﬁ gures 2 and 3). 
The burden of syphilis in pregnancy was greatest in 
Africa, representing 63·1% of global maternal infections 
(585 664; 1·68% prevalence) and 64·0% of adverse 
outcomes (224 761; 0·66%), and was lowest in Europe, 
representing 2·0% of maternal infections (18 437; 0·15%) 
and 1·2% of adverse outcomes (4307; 0·04%).
Worldwide in 2012, an estimated 84·6% of pregnant 
women with syphilis (779 079 of 927 936 women) attended 
antenatal care at least once, of whom 56·4% were not 
tested for the infection (439 412 of 779 079); these cases 
resulted in 65·1% (228 494) of all 350 915 adverse 
outcomes. 5·0% (39 046 of 779 079) of antenatal care 
attendees with syphilis were tested but not treated, 
resulting in 5·8% (20 304 infants) of all 350 915 adverse 
outcomes. Additionally, 38·6% (300 621 of 779 079) of 
pregnant women with syphilis who were tested and 
treated in antenatal care, but for whom treatment was 
ineﬀ ective (eg, given too late in pregnancy to prevent 
an adverse outcome, or given oral treatment rather 
than suﬃ  cient intramuscular doses of benzathine 
benzylpenicillin) contributed to 7·0% of all adverse 
outcomes (24 711). The 16·0% (148 857 of 927 936) of 
pregnant women with syphilis who did not access 
antenatal care accounted for 22·1% (77 406 of 350 915) of 
adverse outcomes. Overall, 96·6% (896 630 of 927 936) 
of maternal syphilis infections and 98·1% (344 474 of 
350 916) of adverse outcomes occurred in low-income 
and middle-income countries.
From updated 2008 to 2012 estimates, maternal syphilis 
infections and adverse outcomes decreased for all 
scenarios studied (ﬁ gure 4). Using data for all WHO 
member countries, from updated 2008 to 2012 estimates, 
maternal infections decreased by 37·7% (from 
1 488 394 [1·07% prevalence] in 2008 to 927 936 [0·66%] 
in 2012) and adverse outcomes decreased by 39·2% 
Figure 4: Estimated number of maternal syphilis (A) and any associated adverse pregnancy outcome (B) for all countries and only countries with data
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(576 784 in 2008 to 350 915 in 2012). Decreases were 
notable in southeast Asia (80·9% decrease in maternal 
infections; 78·4% decrease in adverse outcomes; ﬁ gures 2 
and 3). The proportion of pregnant women not tested for 
syphilis in antenatal care fell in all regions except Africa 
(which increased by 49·0% from 201 547 to 300 246). 
When we considered only the 73 countries reporting data 
for both 2008 and 2012, we noted a 57·1% decrease in 
maternal infections (1 102 261 to 473 030).
We examined data from the ten countries with the 
greatest numbers of livebirths to assess their eﬀ ect on 
global and regional estimates (appendix). From updated 
2008 to 2012 estimates, the change in seropositivity of 
antenatal care attendees in India (from 2·3% to 0·4%) 
and Indonesia (from 5·8% to 1·2%) resulted in 
489 621 fewer maternal infections and 180 107 fewer 
adverse outcomes. India alone accounted for 65·8% of 
the global diﬀ erence in maternal infections and 64·4% of 
adverse outcomes between updated 2008 and 2012 
estimates.
Excluding India in reanalysis in updated 2008 and 2012 
estimates resulted in a decrease in maternal infections by 
18·1% (from 1 059 327 to 867 924 cases) and in adverse 
outcomes by 17·8% (401 098 to 329 683 cases; ﬁ gure 4). 
Countries with data available for both updated 2008 and 
2012 estimates had a 38·6% decrease in maternal 
infections (from 673 194 to 413 018) and 34·7% decrease 
in adverse outcomes (from 56 781 to 37 094). Even if we 
assumed the higher treatment values reported in 2012 
had also occurred in 2008, adverse outcomes still fell by 
more than 20%.
Discussion
This analysis suggests progress in eliminating mother-
to-child transmission of syphilis, with more than one-
third fewer maternal and congenital syphilis infections 
from 2008 to 2012. Since the launch of the global 
initiative, more countries have introduced universal 
syphilis screening in pregnancy, often using rapid 
syphilis testing algorithms when laboratory capacity is 
limited. More countries have integrated prevention of 
mother-to-child transmission of HIV and syphilis into 
maternal health programmes. Additionally, surveillance 
of antenatal syphilis has improved greatly. India and 
Indonesia represented a large proportion of the global 
decreases; however, decreased surveillance persisted 
even when data for India were excluded.
Despite this positive momentum, syphilis continues to 
aﬀ ect large numbers of pregnant women and result in 
substantial perinatal morbidity and mortality. In 2012, 
nearly 1 million pregnant women had syphilis infections 
and roughly 350 000 had a syphilis-induced adverse 
pregnancy outcome despite incremental improvements 
in screening and treatment. Most syphilis-induced 
pregnancy outcomes were in women who attended 
antenatal care, suggesting that these poor outcomes could 
have been prevented had recommended testing and 
treatment been done. Women and infants in low-income 
and middle-income countries suﬀ ered disproportionately, 
and progress in Africa was especially slow.
Our data suggested improvement in coverage of 
antenatal syphilis screening and treatment from 2008 to 
2012 in most regions worldwide. Nonetheless, many 
countries were far from achieving the global programme 
targets (at least 95% screening in pregnant women and 
95% treatment in women testing positive).30,31 Although 
more than three-quarters of pregnant women with 
syphilis in 2012 had at least one antenatal care visit, 
more than half of these women either did not receive 
syphilis testing or received inadequate treatment 
to prevent congenital syphilis. These systemic 
inadequacies in antenatal care led to nearly 80% of 
global congenital syphilis cases (nearly 275 000 events). 
This shortcoming is a failure of the public health system 
and a clarion call for improving the quality of antenatal 
care services.
Global monitoring is improving, with many more 
countries reporting data for each of the three core 
indicators in 2012 than in 2008. However, 41% of 
countries had not reported syphilis seropositivity data, 
45% had not reported testing coverage, and 62% had not 
reported treatment coverage through the UA/GARPR 
system. Increased eﬀ orts are needed to strengthen 
surveillance and monitoring for the elimination of 
mother-to-child transmission of syphilis.12,32,33
Our analysis has limitations. First, the syphilis 
seropositivity datapoint reported by India and used in the 
updated 2008 estimates might have been spuriously 
high. Three consecutive lower values in UA/GARPR and 
a scientiﬁ c literature review from India on syphilis 
prevalence in pregnancy supports this possibility 
(ﬁ gure 5).33–36 Two studies in India suggest decreases in 
syphilis in pregnancy occurred before 2007. Sethi and co-
authors33 noted that the prevalence of syphilis in 
pregnancy in a tertiary health-care centre in northern 
India decreased from 3·0% in 1996 to 0·84% in 2005. 
Figure 5: Prevalence of syphilis in pregnant women in India from various sources, 1996–201233–36
UA/GARPR=Universal Access and Global AIDS Response Progress Reporting.
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They attributed the decrease to educating women on 
the risks of syphilis in antenatal care, monitoring 
management of sexually transmitted infections, and 
more widespread use of over-the-counter antibiotics. In 
another study, Arora and colleagues34 suggested that 
targeted interventions for female sex workers 
implemented by the National AIDS Control Organization 
and the Avahan Project beginning in 1995 had reduced 
the prevalence of syphilis in young pregnant women 
from 1·3% in 2003 to 0·4% in 2007. Additionally, 
although no peer-reviewed scientiﬁ c literature on 
Indonesia reported syphilis seropositivity in antenatal 
care attendees, the metadata for the UA/GARPR 
datapoints suggested that syphilis surveillance in 
antenatal care settings has expanded since 2008. The 
2008 data were from a pilot project to increase screening 
for HIV and syphilis in antenatal care in three provinces, 
whereas the 2009 data represented an expanded pilot in 
ﬁ ve provinces. Selected for high HIV prevalence, these 
provinces might have a higher prevalence of syphilis 
than the national average. Such challenges in obtaining 
accurate and nationally representative data are unlikely 
to be unique to India and Indonesia.
Second, although completeness of reporting of syphilis 
seropositivity in antenatal care attendees through the 
UA/GARPR system improved from 2008 to 2012, two 
populous countries—Pakistan and the USA—did not 
report to WHO during this period. Pakistan does not 
currently have a policy of universal syphilis screening in 
antenatal care, so nationally representative, routinely 
collected data are unavailable. One local study of syphilis 
seropositivity in antenatal care attendees in Karachi, 
Pakistan, reported 0·9%, which is substantially greater 
than the regional mean (0·2%) for the eastern 
Mediterranean region.37 The USA did not report antenatal 
syphilis data to UA/GARPR, but the US national case 
reporting system in 2012 recorded 659 fewer congenital 
syphilis cases than our 2012 estimates of adverse 
pregnancy outcomes.38 This discrepancy is not substantial 
enough to have had an important eﬀ ect on global or 
regional estimates.
Third, the test type used to deﬁ ne positivity was 
unavailable for one-quarter of syphilis seropositivity 
values. Although we adjusted for test type to account for 
this, this paucity of data increases the uncertainty of our 
estimates. Similar data quality issues likely exist for other 
datapoints underlying this modelling exercise, and might 
aﬀ ect our estimates. We hope that future rounds of 
estimates will be able to better explore ways to capture 
this uncertainty.
Finally, interpretation of trends in treatment coverage 
is diﬃ  cult because we did not have country-reported data 
for 2008, and relied on regional treatment assumptions. 
For example, in Africa, although we are conﬁ dent that 
screening decreased regionally from 2008 to 2012, we 
cannot be certain that treatment of maternal syphilis 
worsened over time.
In summary, these new global estimates of maternal 
and congenital syphilis suggest decreases from 2008 to 
2012 worldwide and across most WHO regions. However, 
our ﬁ ndings also suggest that untreated maternal syphilis 
remains a substantial cause of preventable perinatal 
morbidity and mortality. Progress was especially limited 
in Africa, the region with the greatest congenital syphilis 
burden. Improving access to and the quality of early 
antenatal care, increasing syphilis testing at ﬁ rst 
antenatal care visit, ensuring adequate and prompt 
treatment for infected women and their partners, and 
expanding programmes of targeted interventions for 
high-risk groups are necessary to improve control of the 
elimination of mother-to-child transmission of syphilis. 
Additionally, nationally representative data on the three 
core indicators are important for understanding global, 
regional, and country-level progress in eliminating this 
old, but still important, public health problem.
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